FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of NeuroVive Pharmaceutical

NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy

04-Oct-2011 - NeuroVive Pharmaceutical AB and to-BBB have been awarded a grant of €1 million through the Eureka Eurostars program for the joint development of therapies for stroke and other acute neurological conditions.The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB technologies, a grant ...

NeuroVive stroke traumatic brain injuries

Selcia and NeuroVive to Develop New Mitochondrial Medicines for Chronic and Acute Diseases

20-Sep-2011 - Selcia Limited and NeuroVive Pharmaceutical AB have signed a significant research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology. The collaboration is focused on mitochondrial medicine, an emerging therapeutic modality ...

mitochondria research collaborations

NeuroVive Obtains U.S. Orphan Drug Designation for Traumatic Brain Injury

07-Dec-2010 - NeuroVive Pharmaceutical AB (NVP) announced that the U.S. FDA Office of Orphan Products Development has granted an Orphan Drug Designation to the company's NeuroSTAT® (cyclosporine) product for the treatment of moderate to severe traumatic brain injury. The Orphan Drug Designation covers both ...

NeuroVive and to-BBB to jointly develop therapy for stroke

27-Oct-2010 - NeuroVive Pharmaceutical and to-BBB are entering into a joint program to develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies. NeuroVive Pharmaceutical is engaged in research and development of nerve cell-protecting and regenerative ...

brain disorders central nervous system CNS disorders +7

NeuroVive receives Orphan Drug Designation in Europe for moderate and severe traumatic brain injury

13-Oct-2010 - The European Commission has granted Orphan Medicinal Product Designation status to NeuroVive Pharmaceutical AB's product NeuroSTAT® for the treatment of patients with moderate and severe traumatic brain injury. This follows the positive opinion of the European Medicines Agency EMA in July. Orphan ...

AGES mitochondria Orphan Drug Designation